Skip to main content
. 2022 Mar 3;10(3):472. doi: 10.3390/healthcare10030472

Figure 2.

Figure 2

(A) The disease-free survival (DFS) rate is shown for patients with KRAS wild-type versus KRAS mutated versus Impractical KRAS tumours. (B) The overall survival (OS) rate is shown for patients with KRAS wild-type versus KRAS mutated versus Impractical KRAS tumours. (C) The hepatic recurrence rate is shown for patients with KRAS wild-type versus KRAS mutated versus Impractical KRAS tumours. Truncates at 120 months. 95% CI indicates 95% confidence interval.